Home » Stocks » RARE

Ultragenyx Pharmaceutical Inc. (RARE)

Stock Price: $114.53 USD -1.18 (-1.02%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 7.68B
Revenue (ttm) 334.12M
Net Income (ttm) -203.68M
Shares Out 67.10M
EPS (ttm) -3.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $114.53
Previous Close $115.71
Change ($) -1.18
Change (%) -1.02%
Day's Open 113.67
Day's Range 112.05 - 117.50
Day's Volume 664,271
52-Week Range 61.96 - 179.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows

2 days ago - Zacks Investment Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -62.40% and 33.03%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

3 days ago - Zacks Investment Research

First quarter 2021 total revenue of $99.4 million and Crysvita 1 revenue to Ultragenyx of $42.1 million

3 days ago - GlobeNewsWire

NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri...

1 week ago - GlobeNewsWire

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rar...

1 week ago - GlobeNewsWire

NOVATO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

1 week ago - GlobeNewsWire

SAN DIEGO--(BUSINESS WIRE)-- #ASOs--n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases

1 month ago - Business Wire

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

The FDA clears Ultragenyx's (RARE) investigational new drug application for UX053 being developed to treat Glycogen Storage Disease Type III.

1 month ago - Zacks Investment Research

NOVATO, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serio...

2 months ago - GlobeNewsWire

NOVATO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seriou...

2 months ago - GlobeNewsWire

Health Canada approves Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fat...

2 months ago - Benzinga

First Approved Treatment for Adult and Pediatric Patients with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) in Canada First Approved Treatment for Adult and Pediatric Patients with Long-chain Fat...

2 months ago - GlobeNewsWire

Ultragenyx (RARE) reports a narrower year-over-year loss and sales beat estimates in the fourth quarter of 2020.

2 months ago - Zacks Investment Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -26.42% and 28.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 77.16% over the past year to ($0.37), whic...

2 months ago - Benzinga

2020 total revenue of $271.0 million and 2020 Crysvita 1 revenue to Ultragenyx of $138.9 million

2 months ago - GlobeNewsWire

NOVATO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare ...

3 months ago - GlobeNewsWire

Ultragenyx's (RARE) IND application for UX701 for the treatment of Wilson Disease gets FDA clearance.

3 months ago - Zacks Investment Research

Clinical trial will utilize a single-protocol Phase 1/2/3 design

3 months ago - GlobeNewsWire

Ultragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same.

3 months ago - Zacks Investment Research

Durable and Clinically Meaningful Responses Reported from Phase 1/2 Studies of DTX401 for GSDIa and DTX301 for OTC

3 months ago - GlobeNewsWire

NOVATO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare ...

4 months ago - GlobeNewsWire

Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.

4 months ago - Zacks Investment Research

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

Other stocks mentioned: FATE, MRNA, MRSN, NTLA
4 months ago - Zacks Investment Research

Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.

Other stocks mentioned: AMRS, CNSP, CYRN, MREO, NGD, XELA
4 months ago - InvestorPlace

The recent acquisition of rare dug heavyweight Alexion Pharmaceuticals signals a willingness of big pharma to enter the field. Typically, big pharma was interested in larger patient populations however ...

4 months ago - Seeking Alpha

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Other stocks mentioned: EDIT, FATE, FOLD, XLRN
4 months ago - Zacks Investment Research

Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.

4 months ago - Zacks Investment Research

Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx's existing bone franchise

4 months ago - GlobeNewsWire

Ultragenyx (RARE) gets Orphan Drug Designation from the FDA for UX701 for the treatment of Wilson disease.

4 months ago - Zacks Investment Research

NOVATO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare a...

4 months ago - GlobeNewsWire

Results presented at Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit

5 months ago - GlobeNewsWire

NOVATO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seriou...

5 months ago - GlobeNewsWire

State-of-the-art facility to be located in Bedford, Massachusetts

5 months ago - GlobeNewsWire

NOVATO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seriou...

6 months ago - GlobeNewsWire

NOVATO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...

6 months ago - GlobeNewsWire

Stock Market Crumbles; Indexes Dive, More Leaders Break; Monolithic Power, Ultragenyx Strong

YouTube video

Stock market crumbles: Indexes Dive More Leaders Break; Monolithic Power, Ultragenyx strong. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, ...

Other stocks mentioned: MPWR
6 months ago - Investors Business Daily

NOVATO, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...

6 months ago - GlobeNewsWire

Ultragenyx (RARE) reports a narrower loss year over year and sales beat estimates in the third quarter of 2020.

6 months ago - Zacks Investment Research

NOVATO, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...

6 months ago - GlobeNewsWire

Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Ultragenyx (RARE) delivered earnings and revenue surprises of 8.87% and 47.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Ultragenyx Pharmaceutical posted third-quarter results late Tuesday that beat views on the top and bottom lines after RARE stock hit a nearly five-year high, revenue more than triples. The post Ultragen...

6 months ago - Investors Business Daily

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 42.35% over the past year to ($1.13),...

6 months ago - Benzinga

Third quarter 2020 total revenue of $ 81.5 million and Crysvita 1 revenue of $37.3 million

6 months ago - GlobeNewsWire

Efficacy in multiple functional measures observed in all five patients treated

6 months ago - GlobeNewsWire

- Collaboration combines Solid's differentiated microdystrophin construct and Ultragenyx's HeL a PCL manufacturing platform for use with AAV8 and variants -

6 months ago - GlobeNewsWire

NOVATO, Calif. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serio...

6 months ago - GlobeNewsWire

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolv... [Read more...]

Industry
Biotechnology
IPO Date
Jan 31, 2014
CEO
Emil Kakkis
Employees
893
Stock Exchange
NASDAQ
Ticker Symbol
RARE
Full Company Profile

Financial Performance

In 2020, RARE's revenue was $271.03 million, an increase of 161.32% compared to the previous year's $103.71 million. Losses were -$186.57 million, -53.67% less than in 2019.

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for RARE stock is "Buy." The 12-month stock price forecast is 153.19, which is an increase of 33.76% from the latest price.

Price Target
$153.19
(33.76% upside)
Analyst Consensus: Buy